Canyon Pharmaceuticals' DESIR-ABLE Study Completed  
10/10/2012 8:56:06 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--DESIR-ABLE, a multicenter, open-label, single-arm study of desirudin (RevascĀ®, IprivaskĀ®) demonstrated the clinical utility and safety profile of desirudin for prevention of dangerous blood clots in a broad population of surgical and medically ill patients. Results of the study, entitled Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE), were published in Clinical and Applied Thrombosis and Hemostasis.